"Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy".
Stanley R. Riddell
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109
Address correspondence to Stanley R. Riddell, Program in Immunology, D3-110, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109. Phone: (206) 667-5249; Fax: (206) 667-7983; email: sriddell@fhcrc.org
A goal in cancer therapeutics is to develop targeted modalities that
distinguish malignant from normal cells. T cells can discriminate
diseased
cells based on subtle alterations in peptides displayed in association
with
MHC molecules at the cell surface. Recent success using the adoptive
transfer of tumor-specific T cells has fueled optimism that this
approach
may find a place as a targeted therapy for some human cancers.
Additional References:
1. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau
A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK,
Rooney CM, and Heslop HE
"Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+
Hodgkin's Disease",
J.
Exp. Med. 2004 200: 1623-1633. Published online Dec 20 2004, 10.1084/jem.20040890.
2. Links to Hodgkin Lymphoma Immuno-Pathology:
3. Links to Activated T-Lymphocyte Immunotherapy:
Links to
Euchromatin Activator RNA Reviews:
Links to
Euchromatin Activator RNA Research:
Links to Ultrastructural
Probes of DNase I-Sensitive Sites:
Links to
RNA as a Therapeutic Agent:
Links to Hodgkin Lymphoma
Immuno-Pathology:
Links to Activated
T-Lymphocyte Immunotherapy:
Links to Medical
Systems Biology:
Links to Selective
Gene Transcription:
Links to RNA-Induced
Epigenetics:
Links to RNA-Induced
Embryogenesis:
Links to RNA and
Biological Causality:
Links to Reprogramming
and Neoplasia:
A Brief History of Activator RNA:
"Ultrastructural Probes of Active DNA Sites, and the RNA Activators of DNA". (PowerPoint Presentation).